Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)

详细信息    查看全文

• 作者：Ghassan K. Abou-Alfa ; Chia-Jui Yen ; Chih-Hung Hsu…
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：79
• 期：2
• 页码：421-429
• 全文大小：
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Oncology; Pharmacology/Toxicology; Cancer Research;
• 出版者：Springer Berlin Heidelberg
• ISSN：1432-0843
• 卷排序：79

文摘

PurposeCodrituzumab, a humanized antibody against glypican-3, is highly expressed in HCC. A phase I study evaluated the combination with sorafenib in HCC.